FDA approves RNS Neurostimulation System (Neuropace) for uncontrolled seizures
NeuroPace, Inc. has announced that the FDA has on 14 November 2013, granted premarket approval for the NeuroPace RNS System, a treatment for adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs. The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures.The FDA�s approval is supported by a three-month randomized control trial of 191 patients with drug-resistant epilepsy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins